139,591 Shares in Aquestive Therapeutics, Inc. (NASDAQ:AQST) Acquired by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 139,591 shares of the company's stock, valued at approximately $498,000. Raymond James Financial Inc. owned about 0.15% of Aquestive Therapeutics at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. State Street Corp raised its position in Aquestive Therapeutics by 52.1% during the 3rd quarter. State Street Corp now owns 1,496,739 shares of the company's stock worth $7,454,000 after buying an additional 512,682 shares during the last quarter. Harvey Capital Management Inc. increased its stake in shares of Aquestive Therapeutics by 1,419.3% in the fourth quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company's stock worth $952,000 after acquiring an additional 249,790 shares during the period. Verition Fund Management LLC purchased a new position in shares of Aquestive Therapeutics during the third quarter worth $995,000. Wellington Management Group LLP acquired a new position in Aquestive Therapeutics during the third quarter valued at $922,000. Finally, Geode Capital Management LLC boosted its holdings in Aquestive Therapeutics by 5.7% in the third quarter. Geode Capital Management LLC now owns 1,667,515 shares of the company's stock valued at $8,306,000 after purchasing an additional 90,543 shares during the last quarter. 32.45% of the stock is owned by institutional investors and hedge funds.

Aquestive Therapeutics Stock Performance

Shares of NASDAQ:AQST traded up $0.05 during midday trading on Friday, reaching $2.47. 1,299,873 shares of the company's stock traded hands, compared to its average volume of 1,584,976. The company has a fifty day simple moving average of $2.89 and a two-hundred day simple moving average of $3.77. Aquestive Therapeutics, Inc. has a 1 year low of $2.20 and a 1 year high of $5.80. The company has a market cap of $244.21 million, a P/E ratio of -5.49 and a beta of 2.59.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.05). The business had revenue of $11.87 million for the quarter, compared to the consensus estimate of $13.11 million. As a group, research analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on AQST. Cantor Fitzgerald assumed coverage on Aquestive Therapeutics in a research note on Tuesday, December 17th. They set an "overweight" rating and a $17.00 price objective for the company. Alliance Global Partners reissued a "buy" rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Raymond James set a $7.00 price objective on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Lake Street Capital decreased their target price on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, March 7th. Finally, HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research report on Wednesday, April 2nd. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Aquestive Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $10.67.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.